Moritz Schmidt

Title: Moritz Schmidt: Innovator in RNA-Programmable Endonuclease Systems

Introduction

Moritz Schmidt is a prominent inventor based in Cologne, Germany. He has made significant contributions to the field of genetic engineering, particularly in the development of RNA-programmable endonuclease systems. With a total of 2 patents, his work is paving the way for advancements in genome editing technologies.

Latest Patents

Schmidt's latest patents include innovative systems for targeting, editing, or manipulating DNA within cells. One of his notable inventions is the RNA-programmable endonuclease systems and uses thereof. This invention focuses on novel systems utilizing synthetic RNA-guided nucleases (sRGNs) derived from wildtype or parental small type II CRISPR Cas9 endonucleases. Another significant patent is related to RNA-programmable endonuclease systems and their application in genome editing. This invention comprises one or more heterologous vectors encoding a SluCas9 nuclease and guide RNAs (gRNAs), showcasing his expertise in the field.

Career Highlights

Throughout his career, Moritz Schmidt has worked with leading companies in the biotechnology sector. He has been associated with Bayer Healthcare LLC and Crispr Therapeutics AG, where he has contributed to groundbreaking research and development in genetic engineering.

Collaborations

Schmidt has collaborated with notable professionals in his field, including Andre Cohnen and Wayne Coco. These partnerships have further enhanced his research and innovation capabilities.

Conclusion

Moritz Schmidt is a key figure in the development of RNA-programmable endonuclease systems, with a focus on advancing genome editing technologies. His contributions are vital to the ongoing evolution of genetic engineering.